Twelve-year trend in the prevalence of high-risk human papillomavirus infection among rwandan women living with HIV

Gad Murenzi; Faustin Kanyabwisha; Anthere Murangwa; Gallican Kubwimana; Leon Mutesa; Robert D. Burk; Kathryn Anastos; Philip E. Castle

doi:10.1093/infdis/jiaa065

Twelve-year trend in the prevalence of high-risk human papillomavirus infection among rwandan women living with HIV

Gad Murenzi, Faustin Kanyabwisha, Anthere Murangwa, Gallican Kubwimana, Leon Mutesa, Robert D. Burk, Kathryn Anastos, Philip E. Castle

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Background: We examined the trend in prevalence of high-risk human papillomavirus (hrHPV) cervical infection among Rwandan women living with HIV (WLWH) over 12 years. Methods. Prevalence of cervical hrHPV DNA was measured in 3 studies at 3 different time periods in 3 different groups of WLWH using 3 different but comparable hrHPV tests: a MY09/MY11 PCR test in 2005 (RWISA; n = 497), careHPV in 2009-2010 (HPV Demonstration; n = 1242), and Xpert HPV test in 2016-2018 (U54; n = 4734). Prevalences were adjusted for age and CD4 cell count. Results. HrHPV prevalence decreased over time from 42.5% to 32.2% to 26.5% (P <.001). CD4 cell counts improved over time (P_trend <.001) so that the percentage of WLWH with CD4 counts of ≥500 cells/μL increased from 7.7% in 2005 to 42.2% in 2009-2010 and 61.1% in 2016-2018. Thus, after adjustment for differences in CD4 counts and age, hrHPV prevalences were more similar over time: 32.6% for RWISA, 30.6% for HPV Demonstration, and 27.1% for U54 (P =.007). Conclusions. Prevalence of hrHPV among WLWH has decreased over the past decade, most likely the result of improved immune reconstitution due to better HIV care and management in Rwanda.

Original language	English (US)
Pages (from-to)	74-81
Number of pages	8
Journal	Journal of Infectious Diseases
Volume	222
Issue number	1
DOIs	https://doi.org/10.1093/infdis/jiaa065
State	Published - Jun 16 2020

Keywords

Antiretroviral therapy (ART)
CD4
Cervical cancer
Human immunodeficiency virus (HIV)
Human papillomavirus (HPV)
Rwanda
Sub-Saharan Africa

ASJC Scopus subject areas

Immunology and Allergy
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/infdis/jiaa065

Cite this

@article{46843f1c0c9f4deb96c0a05824ff8912,

title = "Twelve-year trend in the prevalence of high-risk human papillomavirus infection among rwandan women living with HIV",

abstract = "Background: We examined the trend in prevalence of high-risk human papillomavirus (hrHPV) cervical infection among Rwandan women living with HIV (WLWH) over 12 years. Methods. Prevalence of cervical hrHPV DNA was measured in 3 studies at 3 different time periods in 3 different groups of WLWH using 3 different but comparable hrHPV tests: a MY09/MY11 PCR test in 2005 (RWISA; n = 497), careHPV in 2009-2010 (HPV Demonstration; n = 1242), and Xpert HPV test in 2016-2018 (U54; n = 4734). Prevalences were adjusted for age and CD4 cell count. Results. HrHPV prevalence decreased over time from 42.5% to 32.2% to 26.5% (P <.001). CD4 cell counts improved over time (Ptrend <.001) so that the percentage of WLWH with CD4 counts of ≥500 cells/μL increased from 7.7% in 2005 to 42.2% in 2009-2010 and 61.1% in 2016-2018. Thus, after adjustment for differences in CD4 counts and age, hrHPV prevalences were more similar over time: 32.6% for RWISA, 30.6% for HPV Demonstration, and 27.1% for U54 (P =.007). Conclusions. Prevalence of hrHPV among WLWH has decreased over the past decade, most likely the result of improved immune reconstitution due to better HIV care and management in Rwanda.",

keywords = "Antiretroviral therapy (ART), CD4, Cervical cancer, Human immunodeficiency virus (HIV), Human papillomavirus (HPV), Rwanda, Sub-Saharan Africa",

author = "Gad Murenzi and Faustin Kanyabwisha and Anthere Murangwa and Gallican Kubwimana and Leon Mutesa and Burk, {Robert D.} and Kathryn Anastos and Castle, {Philip E.}",

note = "Funding Information: Financial support. This work was supported by the National Institutes of Health (NIH) National Cancer Institute (grant number 5U54CA19016304) and NIH National Institute of Allergy and Infectious Diseases (grant number 5U01AI096299-09). Publisher Copyright: {\textcopyright} The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society",

year = "2020",

month = jun,

day = "16",

doi = "10.1093/infdis/jiaa065",

language = "English (US)",

volume = "222",

pages = "74--81",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Twelve-year trend in the prevalence of high-risk human papillomavirus infection among rwandan women living with HIV

AU - Murenzi, Gad

AU - Kanyabwisha, Faustin

AU - Murangwa, Anthere

AU - Kubwimana, Gallican

AU - Mutesa, Leon

AU - Burk, Robert D.

AU - Anastos, Kathryn

AU - Castle, Philip E.

N1 - Funding Information: Financial support. This work was supported by the National Institutes of Health (NIH) National Cancer Institute (grant number 5U54CA19016304) and NIH National Institute of Allergy and Infectious Diseases (grant number 5U01AI096299-09). Publisher Copyright: © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society

PY - 2020/6/16

Y1 - 2020/6/16

N2 - Background: We examined the trend in prevalence of high-risk human papillomavirus (hrHPV) cervical infection among Rwandan women living with HIV (WLWH) over 12 years. Methods. Prevalence of cervical hrHPV DNA was measured in 3 studies at 3 different time periods in 3 different groups of WLWH using 3 different but comparable hrHPV tests: a MY09/MY11 PCR test in 2005 (RWISA; n = 497), careHPV in 2009-2010 (HPV Demonstration; n = 1242), and Xpert HPV test in 2016-2018 (U54; n = 4734). Prevalences were adjusted for age and CD4 cell count. Results. HrHPV prevalence decreased over time from 42.5% to 32.2% to 26.5% (P <.001). CD4 cell counts improved over time (Ptrend <.001) so that the percentage of WLWH with CD4 counts of ≥500 cells/μL increased from 7.7% in 2005 to 42.2% in 2009-2010 and 61.1% in 2016-2018. Thus, after adjustment for differences in CD4 counts and age, hrHPV prevalences were more similar over time: 32.6% for RWISA, 30.6% for HPV Demonstration, and 27.1% for U54 (P =.007). Conclusions. Prevalence of hrHPV among WLWH has decreased over the past decade, most likely the result of improved immune reconstitution due to better HIV care and management in Rwanda.

AB - Background: We examined the trend in prevalence of high-risk human papillomavirus (hrHPV) cervical infection among Rwandan women living with HIV (WLWH) over 12 years. Methods. Prevalence of cervical hrHPV DNA was measured in 3 studies at 3 different time periods in 3 different groups of WLWH using 3 different but comparable hrHPV tests: a MY09/MY11 PCR test in 2005 (RWISA; n = 497), careHPV in 2009-2010 (HPV Demonstration; n = 1242), and Xpert HPV test in 2016-2018 (U54; n = 4734). Prevalences were adjusted for age and CD4 cell count. Results. HrHPV prevalence decreased over time from 42.5% to 32.2% to 26.5% (P <.001). CD4 cell counts improved over time (Ptrend <.001) so that the percentage of WLWH with CD4 counts of ≥500 cells/μL increased from 7.7% in 2005 to 42.2% in 2009-2010 and 61.1% in 2016-2018. Thus, after adjustment for differences in CD4 counts and age, hrHPV prevalences were more similar over time: 32.6% for RWISA, 30.6% for HPV Demonstration, and 27.1% for U54 (P =.007). Conclusions. Prevalence of hrHPV among WLWH has decreased over the past decade, most likely the result of improved immune reconstitution due to better HIV care and management in Rwanda.

KW - Antiretroviral therapy (ART)

KW - CD4

KW - Cervical cancer

KW - Human immunodeficiency virus (HIV)

KW - Human papillomavirus (HPV)

KW - Rwanda

KW - Sub-Saharan Africa

UR - http://www.scopus.com/inward/record.url?scp=85085715031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085715031&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiaa065

DO - 10.1093/infdis/jiaa065

M3 - Article

C2 - 32050023

AN - SCOPUS:85085715031

SN - 0022-1899

VL - 222

SP - 74

EP - 81

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 1

ER -

Twelve-year trend in the prevalence of high-risk human papillomavirus infection among rwandan women living with HIV

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this